Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,352 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes

NCT04993742
View directory record Official record
Conditions
Placental Dysfunction, Prenatal Stress
Interventions
MOMS Intervention
Behavioral
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

NCT00031551
View directory record Official record
Conditions
Stomatitis
Interventions
Etanercept, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
16 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 22, 2026, 6:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT03596645
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab, Infliximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 6:45 PM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 22, 2026, 6:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Beef and Plant Burger Metabolomics Study

NCT05690061
View directory record Official record
Conditions
Inflammatory Response
Interventions
Grain-Fed Beef Hamburger, Grass-Fed Beef Hamburger, Impossible BurgerTM
Dietary Supplement
Lead sponsor
Utah State University
Other
Eligibility
30 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Early Treatment for Acute ACL Tear

NCT01692756
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tears
Interventions
Kenalog or placebo, Kenalog then Placebo, Kenalog, Placebo
Drug
Lead sponsor
Cale Jacobs
Other
Eligibility
14 Years to 33 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Water With Anti-Inflammatory Capabilities on the Inflammatory Response to Heavy Resistance Exercise

NCT07456683
View directory record Official record
Conditions
Systemic Inflammation, Hydration, Resting Metabolism
Interventions
We made a water with berry essence volatiles (cranberry, blackberry, and blueberry). This was consumed for 6 weeks.
Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

NCT02411656
View directory record Official record
Conditions
Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Malnutrition Associated With Complications After Ileostomy Reversal

NCT03909542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ileostomy
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT06257537
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches, SAM Patch
Device · Drug · Other
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07487831
View directory record Official record
Conditions
Atopic Dermatitis (Eczema), Psoriasis
Interventions
Sodium chloride tablets, Placebo Tablets
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.

NCT04579874
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation, Liver Steatoses
Interventions
LIVERFASt
Diagnostic Test
Lead sponsor
Fibronostics USA, Inc
Other
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Detroit, Michigan • St Louis, Missouri • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

NCT01299259
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Text Message Reminders
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
15 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 22, 2026, 6:45 PM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 22, 2026, 6:45 PM EDT
Active, not recruiting Phase 3 Interventional

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
123
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

NCT02624180
View directory record Official record
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Jul 22, 2026, 6:45 PM EDT
Withdrawn Phase 1 Interventional

Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children

NCT03747718
View directory record Official record
Conditions
Crohn Disease
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 22, 2026, 6:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Acetyl-L-Carnitine in the Treatment of Septic Shock

NCT00592488
View directory record Official record
Conditions
Septic Shock
Interventions
Acetyl-L-Carnitine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Jul 22, 2026, 6:45 PM EDT
Completed No phase listed Observational

Serial Therapeutic and Antifungal Monitoring Protocol

NCT02163889
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jul 22, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo
Drug
Lead sponsor
InDex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 22, 2026, 6:45 PM EDT